In this month’s Drug Topics, correspondent Kathleen Gannon Longo talks with Precision for Value’s Jeremy Schafer on the potentially tremendous impact that value assessments will have on future patient reimbursement decisions. Focusing on oncology treatment, Schafer describes some of the existing value frameworks, including Drug Abacus and ICER, as well as newer, more transparent frameworks emerging, such as the Innovation and Value Initiative (IVI).

To read the complete article, please click here.